Usted buscó: behandlingsarmar (Sueco - Inglés)

i alla behandlingsarmar användes en korttidsverkande β2-adrenoceptoragonist vid behov.
all treatment arms used a short-acting β2 adrenoceptor agonist as needed.

patienterna randomiserades i förhållandet 1:1:1 till en av tre behandlingsarmar.
patients were randomized in a 1:1:1 ratio to one of 3 treatment arms.

jämfört med publicerade data för liknande behandlingar utan pertuzumab observerades höga pcr- frekvenser i alla 3 behandlingsarmar (se tabell 3).
compared with published data for similar regimens without pertuzumab, high pcr rates were observed in all 3 treatment arms (see table 3).

varje dosnivå av mirabegron och moxifloxacin utvärderades i separata behandlingsarmar, inklusive placebokontroll (parallell cross-over design).
each dose level of mirabegron and moxifloxacin was evaluated in separate treatment arms each including placebo-control (parallel cross-over design).

+222 x 106 celler/l i de behandlingsarmar som fick rilpivirin respektive efavirenz (med bakgrundsbehandling emtricitabin/tenofovirdisoproxilfumarat).
222 x 106 cells/l for the rilpivirine and efavirenz treatment arms, respectively, of patients receiving the emtricitabine/tenofovir disoproxil fumarate background regimen.

crossover till den andra behandlingsarmen var tillåten om patienterna visade tecken på sjukdomsprogress eller intolerans som inte kunde hanteras med dosjustering.
crossover to the alternative treatment arm was allowed if patients showed evidence of disease progression or intolerance that could not be managed by dose modification.